Unresectable Breast Cancer
📧 Sign up to get email alerts when something new happens for Unresectable Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial to determine the optimal dose of BNT323 in combination with BNT327 for advanced breast cancer, currently recruiti…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer [NA]
This entry provides an update on the BettER trial, a biomarker-driven early therapeutic selection study in HR+ HER2- metastatic or unresecta…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada
This clinical trial update reports real-world outcomes of trastuzumab deruxtecan (Enhertu) in Canadian patients with unresectable or metasta…
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer [Phase 2]
Phase 2 trial evaluating veliparib with or without carboplatin in patients with stage III or IV breast cancer has completed, with results po…
-
CLINICAL_TRIALS trial_result · 2025-07-22Clinical Trial Update: Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer [Phase 1]
A Phase 1 trial evaluating copanlisib in combination with T-DM1 for pretreated unresectable locally advanced or metastatic HER2-positive bre…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-08-11Clinical Trial Update: Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer [Phase 1, Phase 2]
Clinical trial evaluating atezolizumab with cobimetinib or idasanutlin in stage IV or unresectable recurrent estrogen receptor-positive brea…